Monocentric, Prospective, Doubleblind, Randomized/Stratified, Placebo-Controlled Pilot-Study for Evaluation of Safety and Efficacy of Flupirtine Add-on to Interferon-beta1b on Neurodegeneration in Patients With Relapsing Remitting Multiple Sclerosis.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Flupirtine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms FLORIMS
- 20 Mar 2018 Biomarkers information updated
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jul 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.